02 May 2003
Treatment of INS-1 pancreatic b-cells with poly(ADP-ribose) polymerase (PARP) inhibitors attenuates glucose-induced changes in insulin and lipogenic gene expression
L. Olson, K. Linning, D. Jump, D. YeMed Sci Monit 2003; 9(1): 51-0 :: ID: 15114
Abstract
Chronic hyperglycemia can alter pancreatic b-cell phenotype by decreasing expression of b-cell specific genes including insulin and GLUT2, while increasing expression of metabolic genes normally not abundantly expressed such as l-pyruvate kinase (l-PK), fatty acid synthase (FAS), acetyl-CoA carboxylase, and lactate dehydrogenase. Treatment of INS-1 pancreatic b-cells with high glucose (16.7 mM) for 48 hrs markedly suppressed insulin promoter activity [1] and induced l-PK promoter activity [1,2]. High glucose also elevated intracellular NAD levels 2-fold compared to control. PARP, an enzyme that uses NAD to poly(ADP-ribosy)late nuclear proteins [3], has been suggested to be involved in ß-cell cytotoxicity, regeneration and differentiation [2,4], and adipocyte differentiation [5]. Thus, we examined the ability of PARP inhibitors – nicotinamide (NAM), 3-aminobenzamide (3-AB), and PD128763 (PD) – to attenuate glucose-mediated changes in insulin and lipogenic gene expression and promoter activities in INS-1 cells. Incubation of INS-1 cells in high glucose for 48 hrs suppressed in suppressed insulin mRNA level >80% and induced l-PK, FAS, and SREBP-1c mRNA levels 4.4-, 12.6-, and 2.7-fold, respectively. Treatment with high glucose concentrations also repressed insulin (–327/+30) promoter activity >80%, and induced l-PK (–4.3 kb/+12) and FAS (–2.4 kb/+16) promoter activity 24- and 21-fold, respectively. Treatment of cells with high glucose plus 10 mM NAM, 10 mM 3-AB, or 500 KM PD, increased insulin mRNA levels and promoter activity 3.4- and 10-fold, respectively. PARP inhibitors also attenuated glucose-mediated induction of l-PK, FAS, and SREBP-1c mRNA levels by 55%, 69%, and 45%, respectively. Moreover, PARP inhibitors attenuated the ability of high glucose to activate l-PK and FAS promoters by 51% and 61%, respectively. These results indicate that PARP inhibitors can attenuate adverse changes in gene expression that occur when b-cells are exposed to elevated glucose concentrations.References: 1.Olson LK, Qian J, Poitout V: Mol Endocrinol, 1998; 12(2): 207-219 2.Newburg E, Qian J, Towle HC, Olson LK: Mol Cell Biochem, 2000; 210: 13-21 3.Virag L, Szabo C: Pharmacol Rev, 2002; 54(3): 375-429 4.Okamoto H, Takasawa S: Diabetes, 2002; 51(suppl. 3): S462-S473 5.Smulson ME, Kang VH, Ntambi JM et al: J Biol Chem, 1995; 270(1): 119-127
Keywords: PARP inhibitors, b-cell phenotype, islet of langerhans, Glucose, insulin gene, lipogenic genes
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Review article
Global Guidelines and Trends in HPV Vaccination for Cervical Cancer PreventionMed Sci Monit In Press; DOI: 10.12659/MSM.947173
Clinical Research
Serum Prolidase and Ischemia-Modified Albumin Levels in Neural Tube Defects: A Comparative Study of Myelome...Med Sci Monit In Press; DOI: 10.12659/MSM.947873
Clinical Research
Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.947630
Clinical Research
Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...Med Sci Monit In Press; DOI: 10.12659/MSM.947450
Most Viewed Current Articles
17 Jan 2024 : Review article 7,960,158
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,953
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 29,945
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 23,915
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912